Next-Generation Sequencing Data Analysis Market Report 2026

The next-generation sequencing data analysis market size has grown exponentially in recent years. It will grow from $1.48 billion in 2025 to $1.8 billion in 2026 at a compound annual growth rate (CAGR) of 21.9%. The growth in the historic period can be attributed to growth in ngs data generation volumes, increasing use of genomic data in research, expansion of clinical sequencing programs, improvements in computational infrastructure, rising adoption of outsourced bioinformatics services.

The next-generation sequencing data analysis market size is expected to see exponential growth in the next few years. It will grow to $3.93 billion in 2030 at a compound annual growth rate (CAGR) of 21.5%. The growth in the forecast period can be attributed to increasing integration of ai in variant interpretation, rising demand for real-time genomic insights, expansion of personalized medicine applications, growing investments in secure genomic data platforms, increasing regulatory focus on data compliance. Major trends in the forecast period include increasing adoption of AI-driven bioinformatics platforms, rising demand for cloud-based ngs data analysis, growing use of long-read sequencing analytics, expansion of integrated genomic pipelines, enhanced focus on data interpretation accuracy.

The rising prevalence of cancer is anticipated to drive the growth of the next-generation sequencing data analysis market in the coming years. Cancer is a broad category of diseases marked by the uncontrolled growth and spread of abnormal cells within the body, which can result in severe health complications or death if left untreated. Unhealthy lifestyle choices, such as tobacco use, excessive alcohol intake, and diets high in processed foods but low in fruits and vegetables, significantly elevate the risk of developing cancer. Next-generation sequencing data analysis supports cancer care by accurately identifying genetic mutations, enabling personalized treatment approaches and more effective therapies tailored to the unique genetic makeup of an individual’s cancer. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that by 2050, more than 35 million new cancer cases are projected globally, reflecting a 77% increase from the estimated 20 million cases recorded in 2022. As a result, the growing burden of cancer is fueling the expansion of the next-generation sequencing data analysis market.

Major companies operating in the next-generation sequencing data analysis market are concentrating on the development of advanced secondary analysis bioinformatics software to support faster and more accurate identification of genetic variants for both research and clinical use. Secondary analysis bioinformatics software is designed to process raw data generated from next-generation sequencing (NGS) and transform it into interpretable outputs, such as variant call files (VCFs) that describe genetic variations. This software simplifies and accelerates the analysis of NGS data for research and clinical applications. For example, in January 2024, QIAGEN Digital Insights, the US-based bioinformatics division of QIAGEN, introduced the QIAGEN CLC Genomics Workbench Premium powered by LightSpeed technology. The solution supports NGS-based somatic cancer analysis and enables rapid processing of whole genome sequencing (WGS) samples. Using LightSpeed technology, it can analyze 34x human genomes in 25 minutes and 50x exomes in 90 seconds by efficiently converting raw FASTQ data into interpretable formats. With processing costs as low as $1 per genome and only a few cents per exome when using cloud infrastructure, the software offers a cost-effective option for high-throughput laboratories. It operates on standard hardware or cloud environments, delivering flexibility, high accuracy, and suitability for clinical applications while also reducing its carbon footprint.

In January 2023, QIAGEN, a Germany-based provider of sample and assay technologies, acquired Verogen for an undisclosed sum. Through this acquisition, QIAGEN aims to reinforce its presence in the forensic and human identification markets. By securing exclusive distribution rights to Verogen’s MiSeq FGx Sequencing System and its range of forensic kits, along with access to the GEDmatch database and the GEDmatch PRO portal, QIAGEN intends to expand its capabilities in delivering advanced genetic analysis solutions for complex forensic investigations. Verogen is a US-based company that specializes in next-generation sequencing technologies, including data analysis software.

Major companies operating in the next-generation sequencing data analysis market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., MedGenome Inc., Element Biosciences Inc., Seven Bridges Genomics Inc., Synthego Corp., Eurofins Genomics India Pvt. Ltd., Fabric Genomics Inc., Strand Life Sciences Pvt. Ltd., Admera Health LLC, Congenica Ltd., DNASTAR Inc., Golden Helix Inc., Geneious, SciGenom Labs Pvt. Ltd., Partek Incorporated, PathoQuest SAS, BioDatomics Inc., BGI Genomics Co. Ltd.

North America was the largest region in the next-generation sequencing data analysis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing data analysis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation sequencing data analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the NGS data analysis market by increasing costs of imported high-performance computing hardware, specialized servers, data storage systems, and advanced software tools. Research institutions and clinical laboratories in North America and Europe are most affected due to dependence on imported computing infrastructure, while Asia-Pacific faces higher costs for software licensing and system integration. These tariffs are increasing deployment costs and slowing infrastructure upgrades. However, they are also driving local cloud adoption, regional software development, and domestic bioinformatics service expansion.

The next-generation sequencing data analysis market research report is one of a series of new reports that provides next-generation sequencing data analysis market statistics, including next-generation sequencing data analysis industry global market size, regional shares, competitors with a next-generation sequencing data analysis market share, detailed next-generation sequencing data analysis market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing data analysis industry. This next-generation sequencing data analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Next-generation sequencing (NGS) data analysis involves interpreting the vast volumes of data produced by high-throughput DNA or RNA sequencing technologies. Its primary objective is to identify genetic variations and mutations, supporting disease detection, biomarker identification, and a deeper understanding of biological processes. This analysis plays a key role in advancing personalized medicine, enabling targeted therapies, and enhancing diagnostic accuracy.

The main product types in next-generation sequencing data analysis include services and commercial NGS software. Services encompass a wide range of professional solutions focused on managing and analyzing complex genomic datasets, helping researchers and clinicians derive meaningful insights from sequencing outputs. Read lengths include short-read, long-read, and very long-read sequencing, delivered through different modes such as in-house and outsourced. These solutions support various workflows, including primary, secondary, and tertiary analysis, and are utilized by multiple end users, such as academic research institutions, clinical research organizations, hospitals and clinics, pharmaceutical and biotechnology companies, and others.

The next-generation sequencing data analysis market consists of revenues earned by entities by providing services such as data processing, sequence alignment, gene expression analysis, genomic profiling, report generation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.